Few and far between have been product launches at Lundbeck the past few years, including the three years led by Deborah Dunsire, with the only new launch being that of Vyepti, which is – for Lundbeck – a relatively new area: migraine.
Lundbeck, under the leadership of Dunsire, has chosen this approach in particular because of the problems with the lack of launches. The company has suffered several failures with substances in late stages, of which idalopirdine and Lu AF35700 have been the most noteworthy. This is a statistic that Dunsire is set on changing.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.